SCHEMBL827805

SCHEMBL827805

CC(=O)c1ccc(-c2nc(Nc3ccc(F)c(F)c3)nn2C[C@H](C)O)cn1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KCNH2 Q12809 6/20 0.35
▸ TGFBR1 P36897 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ CDK2 P24941 3/20 0.34
▸ CDK4 P11802 1/20 0.34
▸ CDKL1 Q00532 1/20 0.34
▸ KCNQ3 O43525 1/20 0.33
▸ KCNQ2 O43526 1/20 0.33
▸ MALT1 Q9UDY8 1/20 0.33
▸ KCNJ6 P48051 1/20 0.33
▸ KCNJ5 P48544 1/20 0.33
▸ KCNJ3 P48549 1/20 0.33
▸ JAK2 O60674 2/20 0.33
▸ JAK3 P52333 2/20 0.33
▸ PTK2 Q05397 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL827742 0.91 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KCNH2CDK2
SCHEMBL827758 0.91 NPC1 (0.39) NPC1RAB9ASMN1; SMN2KCNH2TGFBR1
SCHEMBL827973 0.87 KCNQ3 (0.39) NPC1RAB9ASMN1; SMN2TGFBR1GSK3B
SCHEMBL827997 0.84 SYK (0.39) TGFBR1GSK3BJAK2JAK3PTK2
SCHEMBL3030717 0.73 KDM4E (0.36) NPC1RAB9ASMN1; SMN2KCNH2ALDH1A1
SCHEMBL3657282 0.73 KDM4E (0.36) NPC1RAB9ASMN1; SMN2KCNH2ALDH1A1
SCHEMBL3030724 0.73 KDM4E (0.36) NPC1RAB9ASMN1; SMN2KCNH2ALDH1A1
SCHEMBL3657283 0.73 KDM4E (0.36) NPC1RAB9ASMN1; SMN2KCNH2ALDH1A1
SCHEMBL827490 0.70 TGFBR1 (0.34) KCNH2TGFBR1GSK3BCDK2CDK4
SCHEMBL3032363 0.69 KDM4E (0.34) NPC1RAB9ASMN1; SMN2ALDH1A1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 — — US disclosed
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 — — US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 — — US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES CHRNA1, CHRNA5, CHRNA3 NPC1 2263/4885RAB9A 1835/4885SMN1; SMN2 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback